Who are Lansoprazole and naproxen and aspirin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lansoprazole-and-naproxen-and-aspirin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Lansoprazole and naproxen and aspirin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lansoprazole and naproxen and aspirin (Lansoprazole and naproxen and aspirin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor + NSAID combination. Area: Gastroenterology / Rheumatology.

phase 3 Proton pump inhibitor + NSAID combination H+/K+-ATPase (lansoprazole); COX-1 and COX-2 (naproxen and aspirin) Gastroenterology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Lansoprazole and naproxen and aspirin (Lansoprazole and naproxen and aspirin) — Takeda. This combination product reduces gastric acid secretion via lansoprazole while providing anti-inflammatory and analgesic effects through naproxen and aspirin, with the proton pump inhibitor protecting against NSAID-induced gastrointestinal injury.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lansoprazole and naproxen and aspirin TARGET	Lansoprazole and naproxen and aspirin	Takeda	phase 3	Proton pump inhibitor + NSAID combination	H+/K+-ATPase (lansoprazole); COX-1 and COX-2 (naproxen and aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton pump inhibitor + NSAID combination class)

Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lansoprazole and naproxen and aspirin — Competitive Intelligence Brief. https://druglandscape.com/ci/lansoprazole-and-naproxen-and-aspirin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab